Please assess the completion status of the following clinical trial:

Trial Title: Hormone Therapy and OGX-011 Before Radical Prostatectomy in Treating Patients With Prostate Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the prostate~  * High-risk, localized disease that is previously untreated~ * Minimum of 2 positive biopsies~ * Meets at least 1 of the following criteria:~    * Stage T3~   * Serum PSA greater than 10 ng/mL~   * Gleason score 7-10~   * Gleason score 6 and at least 3 positive biopsies~* Potential candidate for radical prostatectomy~PATIENT CHARACTERISTICS:~Age~* Over 18~Performance status~* ECOG 0-1~Life expectancy~* Not specified~Hematopoietic~* WBC at least 3,000/mm\^3~* Platelet count at least 100,000/mm\^3~* Hemoglobin at least 10.0 g/dL~Hepatic~* Bilirubin normal~* AST and ALT normal~* PTT normal~* INR normal~Renal~* Creatinine normal~Cardiovascular~* No significant cardiac dysfunction~Other~* Fertile patients must use effective contraception~* No known hypersensitivity to oligonucleotides, luteinizing hormone-releasing hormone analogs, or anti-androgens~* No evidence of active uncontrolled infection~* No other malignancy within the past 5 years except adequately treated nonmelanoma skin cancer~* No other serious illness, psychiatric disorder, or medical condition that would preclude study compliance~* No history of a significant neurological disorder that would preclude informed consent~* No geographical condition that would preclude study compliance~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Not specified~Chemotherapy~* No prior chemotherapy for prostate cancer~Endocrine therapy~* No prior hormonal therapy for prostate cancer~Radiotherapy~* No prior radiotherapy for prostate cancer~* No concurrent radiotherapy~Surgery~* Not specified~Other~* No concurrent heparin or warfarin anticoagulation~* No other concurrent investigational therapy~* No other concurrent cytotoxic therapy

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).